Table 3.
Association of decreased BMP-2 expression with clinicopathological characteristics in 90 patients treated with radical prostatectomy for prostate cancer.
| Variable | BMP-2 status | p-value | |
|---|---|---|---|
| Normal group (High and moderate expression) (N = 58) | Decreased group (Absent and Weak expression) (N = 32) | ||
| Mean age, years | 62.50 ± 5.98 | 62.94 ± 6.84 | 0.753 |
| Mean PSA ± S.D | 9.46 ± 6.85 | 8.41 ± 3.72 | 0.423 |
| BMP expression (%) | 44.83 ± 11.87 | 17.17 ± 0.82 | 0.001 |
| Pathological tumour stage, n (%) | 0.102 | ||
| ≤pT2c | 51 (87.9%) | 24 (75.0%) | |
| >pT2c | 7 (12.1%) | 8 (25.0%) | |
| Gleason score, n (%) | 0.037 | ||
| 6 | 21 (36.2%) | 7 (21.9%) | |
| 7 | 35 (60.3%) | 19 (59.4%) | |
| ≥8 | 2 (3.4%) | 6 (18.8%) | |
| Biochemical recurrence, n (%) | 18 (31.0%) | 18 (56.3%) | 0.018 |
| Progression to CRPC, n (%) | 1 (1.7%) | 3 (9.4%) | 0.127 |
PSA = prostate specific antigen; BMP = bone morphogenetic proteins; S.D = standard deviation; CRPC = castration resistance prostate cancer.